Early Intervention With Acalabrutinib in Patients With High Risk CLL
Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
This study evaluates the effectiveness of acalabrutinib treatment in patients with chronic
lymphocytic leukemia (CLL) deemed at high risk for Richter's Transformation (RT). This is a
single arm study. Enrolled patients will initiate therapy with acalabrutinib and will dose
continuously. While on study, subjects will be monitored monthly for the first 3 months, then
every three months thereafter until disease progression, discontinuation due to toxicity,
death, or study completion.